Pathophysiology of Human Visceral Obesity: An Update
Патофизиология висцерального ожирения у человека: современный обзор
2013-01-01
SCID: 54.1/csxkej9r
Discuss with AI
cardiometabolic riskectopic triglyceride storageinsulin resistancevisceral adipose tissuevisceral obesity
Figures from the paper
Abstract (AI)
Excess intra-abdominal adipose tissue accumulation, often termed visceral obesity, is part of a phenotype including dysfunctional subcutaneous adipose tissue expansion and ectopic triglyceride storage closely related to clustering cardiometabolic risk factors. Hypertriglyceridemia; increased free fatty acid availability; adipose tissue release of proinflammatory cytokines; liver insulin resistance and inflammation; increased liver VLDL synthesis and secretion; reduced clearance of triglyceride-rich lipoproteins; presence of small, dense LDL particles; and reduced HDL cholesterol levels are among the many metabolic alterations closely related to this condition. Age, gender, genetics, and ethnicity are broad etiological factors contributing to variation in visceral adipose tissue accumulation. Specific mechanisms responsible for proportionally increased visceral fat storage when facing positive energy balance and weight gain may involve sex hormones, local cortisol production in abdominal adipose tissues, endocannabinoids, growth hormone, and dietary fructose. Physiological characteristics of abdominal adipose tissues such as adipocyte size and number, lipolytic responsiveness, lipid storage capacity, and inflammatory cytokine production are significant correlates and even possible determinants of the increased cardiometabolic risk associated with visceral obesity. Thiazolidinediones, estrogen replacement in postmenopausal women, and testosterone replacement in androgen-deficient men have been shown to favorably modulate body fat distribution and cardiometabolic risk to various degrees. However, some of these therapies must now be considered in the context of their serious side effects. Lifestyle interventions leading to weight loss generally induce preferential mobilization of visceral fat. In clinical practice, measuring waist circumference in addition to the body mass index could be helpful for the identification and management of a subgroup of overweight or obese patients at high cardiometabolic risk.
Key Findings
1
Abdominal adipocyte size and number, lipolytic responsiveness, lipid-storage capacity, and inflammatory cytokine production correlate with, and may contribute causally to, cardiometabolic risk.
2
Age, sex, genetics, and ethnicity influence visceral fat accumulation; sex hormones, abdominal cortisol production, endocannabinoids, growth hormone, and dietary fructose may promote disproportionate visceral storage during weight gain.
3
Its metabolic profile includes hypertriglyceridemia, elevated free fatty acids, inflammation, liver insulin resistance, increased VLDL secretion, impaired triglyceride-rich lipoprotein clearance, small dense LDL, and low HDL cholesterol.
4
Lifestyle-induced weight loss generally preferentially mobilizes visceral fat, while waist circumference alongside body mass index may improve identification and management of high-risk overweight individuals.
5
Thiazolidinediones and sex-hormone therapies can improve fat distribution and cardiometabolic risk to varying degrees, but their use is constrained by serious adverse effects.
6
Visceral obesity involves excess intra-abdominal fat, dysfunctional subcutaneous expansion, and ectopic triglyceride storage, clustering major cardiometabolic risk factors.
Research Object
Human visceral obesity, including excess intra-abdominal adipose tissue and associated ectopic triglyceride storage
Research Subject
The pathophysiological mechanisms, metabolic alterations, determinants, cardiometabolic consequences, and modulation of visceral fat accumulation
Publication Details
Publication Date
2013-01-01
Journal
Publisher
ISSN
Cited by
3038
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by6
Obesity Phenotypes, Diabetes, and Cardiovascular Diseases2020
Is Adipose Tissue Inflammation the Culprit of Obesity‐Associated Comorbidities?2025
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)2024
Assessment of plasminogen activator inhibitor-1 in obese Egyptian children2020
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease2023
Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications2019